BioAtla, Inc. (BCAB)
BioAtla Inc. is a biopharmaceutical firm currently in the clinical development phase, focused on creating highly specific and selective antibody-derived treatments designed to combat solid tumor cancers. The company's primary experimental therapeutic, BA3011, is a conditionally active biologic antibody-drug conjugate (CAB ADC) being investigated for its potential against soft tissue and bone sarcoma, non-small cell lung cancer (NSCLC), and ovarian cancer. Additionally, BioAtla is advancing BA3021, another CAB ADC, for a variety of solid malignancies such as NSCLC, melanoma, and ovarian cancer. A third candidate, BA3071, is a conditionally active anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) antibody aimed at a broad spectrum of cancers, including renal cell carcinoma, non-small cell and small cell lung cancers, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. Established in 2007, BioAtla Inc. operates out of San Diego, California.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
BioAtla, Inc.
- Not computed: short interest % needs a single float figure, and the float on record is a bound or estimate.
- 72.0K
- 6.22
The cost to borrow BCAB shares for a short sale and how many IBKR has available, from IBKR's lendable-stock file, refreshed through the session.
- 61.8%
- 277
Off-exchange short volume is not short interest and is not a bearish signal. When a wholesaler fills a retail buy order it sells to the customer as principal and buys back in the market, and that sale is reported as short. A high reported short share is therefore characteristic of internalised retail buying, and this figure should not be read as investors positioning against the stock.
Latest short interest settlements (today's share basis)
| Date | Shares short |
|---|---|
| Oct 30, 2026 | 72.0K sh |
| Oct 15, 2026 | 72.9K sh |
| Sep 30, 2026 | 75.6K sh |
| Sep 15, 2026 | 94.1K sh |
| Aug 31, 2026 | 204.1K sh |
Latest fails to deliver
| Date | Shares failed |
|---|---|
| Oct 23, 2026 | 277 sh |
| Oct 15, 2026 | 5.6K sh |
| Oct 14, 2026 | 5.6K sh |
| Sep 9, 2026 | 100 sh |
| Sep 2, 2026 | 75 sh |
A stock split executed inside this window; every settlement plotted has been carried onto today’s share basis, so the line does not step at the split.
The three panels share one date axis, so a point's position is its date; each has its own value axis. Short interest is plotted on today's share basis, so the line does not step where a split does.
Latest sessions
| Date | Reported short |
|---|---|
| Nov 17, 2026 | 61.8% |
| Nov 16, 2026 | 42.1% |
| Nov 11, 2026 | 17.9% |
| Nov 10, 2026 | 10.2% |
| Nov 9, 2026 | 15.2% |
130 calendar days requested; 84 sessions published. FINRA reports this at T+1 to T+2, so the latest session is not today's.
Source: FINRA Reg SHO daily short volume, summed across the NASDAQ, NYSE and Consolidated trade reporting facilities. Covers off-exchange (over-the-counter) executions only; volume executed on an exchange is not included and is not reported short here.
Off-exchange short volume is not short interest and is not a bearish signal. When a wholesaler fills a retail buy order it sells to the customer as principal and buys back in the market, and that sale is reported as short. A high reported short share is therefore characteristic of internalised retail buying, and this figure should not be read as investors positioning against the stock.
FINRA's weekly alternative trading system (dark pool) volume for BCAB: the share of off-exchange volume that traded on an ATS, and each venue by shares and trades.
As of the Oct 30, 2026 FINRA settlement, 71,975 BCAB shares were sold short (6.22 days to cover).